Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2005-09-08
2010-11-09
Richter, Johann R (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S258100
Reexamination Certificate
active
07829708
ABSTRACT:
The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.
REFERENCES:
patent: 4996207 (1991-02-01), Nair et al.
patent: 5028608 (1991-07-01), Taylor et al.
patent: 5073554 (1991-12-01), Nair
patent: 5248775 (1993-09-01), Taylor et al.
patent: 5344932 (1994-09-01), Taylor
patent: 5534518 (1996-07-01), Henrie, II et al.
patent: 5550128 (1996-08-01), Nair et al.
patent: 5593999 (1997-01-01), Nair et al.
patent: 5866580 (1999-02-01), Gangjee
patent: 5912251 (1999-06-01), Nair
patent: 6048736 (2000-04-01), Kosak
patent: 6667318 (2003-12-01), Burdick et al.
patent: 7060825 (2006-06-01), Wu et al.
patent: 7612071 (2009-11-01), Kamen et al.
patent: 2001/0034333 (2001-10-01), Kosak
patent: 2002/0077280 (2002-06-01), Judice et al.
patent: 2003/0162721 (2003-08-01), Mehlem
patent: 2003/0181635 (2003-09-01), Kochat et al.
patent: 2004/0092739 (2004-05-01), Xiao et al.
patent: 2005/0020833 (2005-01-01), Wu et al.
patent: 2006/0111272 (2006-05-01), Roberts et al.
patent: 2006/0160751 (2006-07-01), McGuire
patent: 0 239 362 (1987-09-01), None
patent: 0 340 905 (1989-11-01), None
patent: WO 93/13079 (1993-07-01), None
patent: WO-02/081455 (2002-10-01), None
Merriam-Webster's Collegiate Dictionary, Merriam-Webster Incorporated: Springfield, Massachusetts, 1993, pp. 311 and 996.
Baugh et al., “Polygammaglutamyl Metabolites of Methotrexate,”Biochemical and Biophysical Research Communications, 1973, pp. 27-34, vol. 52, No. 1.
Jackman, “Antifolate Drugs In Cancer Therapy,”Book Review: Reprints from Current Trends, Drug Discovery Today, 1999.
Montgomery et al., “Design and Synthesis of Folate Analogs as Antimetabolites In Folate Antagonists as Therapeutic Agents,”Biochemistry, Molecular Actions and Synthetic Designs, 1984, pp. 219-261, vol. 1.
Moran et al. “Relative Substrate Activities of Structurally Related Pteridine, Quinazoline, and Pyrimidine Analogs for Mouse Liver Folylpolyglutamate Synthetase,”Molecular Pharmacology, 1989, pp. 736-743, vol. 36, No. 5.
Nair et al., “Metablism Blocked Classical Folate Analog Inhibitors of Dihydrofolate Reductase-1: Synthesis and Biological Evaluation of Mobiletrex,”Medicinal Chemistry Research, 1999, pp. 176-185, vol. 9, No. 3.
Yan et al., “Folic Acid Analogs . III. N-(2[2-(,4-diamino-6-quinazolinyl)ethyl] benzoyl)-L-glutamic acid,”J. Heterocyclic Chem., 1979, 541-544, vol. 16.
Abraham et al., “Aldehyde Oxidase Mediated 7-Hydroxylation of Antifolates and Its Therapeutic Relevance,”Cellular Pharmacology, 1996, vol. 3, pp. 29-34.
Abraham et al., “Folate Analogues. 34. Synthesis and Antitumor Activity of Non-Polyglutamylatable Inhibitors of Dihydrofolate Reductase,”J. Med. Chem., 1991, vol. 34, pp. 222-227.
Amato et al., “Metabolism-Based Antifolate Drug Design: MDAM and MTREX,”Pharmacology and Therapeutics in the New Millennium, 2001, pp. 204-212, Narosa Publishing House, New Delhi, India.
Broxterman et al., “Cancer Research 2001: Drug Resistance, New Targets and Drug Combinations,”Drug Resistance Updates, 2001, vol. 4, pp. 197-209.
Bryant et al., “Metabolism-Blocked Antifolate-2,”Proc. Am. Assoc. Cancer Res., 1999, vol. 40, p. 293 (Abstract No. 1944).
Degraw et al., “Synthesis and Antifolate Activity of 8,10-Dideazaminopterin,”J. Het. Chem., 1982, vol. 19, pp. 1587-1588.
Gangjee et al., “Nonclassical 2,4-Diamino-8-Deazafolate Analogues as Inhibitors of Dihydrofolate Reductases from Rat Liver,Pneumocystis carinii, andToxoplasma gondii,” J. Med. Chem., 1996, vol. 39(9), pp. 1836-1845.
Kisliuk, “Deaza Analogs of Folic Acid as Antitumor Agents,”Current Pharmaceutical Design, 2003, vol. 9(31), pp. 2615-2625.
Lemanske, “Inflammation in Childhood Asthma and Other Wheezing Disorders,”Pediatrics, 2002, vol. 109(2), pp. 368-372.
McGuire, “Anticancer Antifolates: Current Status and Future Directions,”Current Pharmaceutical Design, 2003, vol. 9(31), pp. 2593-2613.
Nagayama et al., “Eosinophils and Basophilic Cells in Sputum and Nasal Smears Taken from Infants and Young Children during Acute Asthma,”Pediatr. Allergy Immunol., 1995, vol. 6, pp. 204-208.
Nair et al., “Metabolism-Blocked Antifolates-1,”Proc. Am. Assoc. Cancer Res., 1998, vol. 39, p. 431 (Abstract No. 2938).
Nair et al., “Polyglutamylation as a Determinant of Cytotoxicity of Classical Folate Analogue Inhibitors of Thymidylate Synthase and Glycinamide Ribonucleotide Formyltransferase,”Cellular Pharmacology, 1994, vol. 1, pp. 245-249.
Renouard et al., “Functionalized Tetradentate Ligands for Ru-Sensitized Solar Cells,”Tetrahedron, 2001, vol. 57, pp. 8145-8150.
Rosowsky et al., “Analogues of Methotrexate and Aminopterin with γ-Methylene and γ-Cyano Substitution of the Glutamate Side Chain: Synthesis and in Vitro Biological Activity,”J. Med. Chem., 1991, vol. 34, pp. 203-208.
Shilai et al., “Selective Metallation of Thiophene and Thiazole Rings with Magnesium Amide Base,”J. Chem. Soc., Perkin Trans. 1, 2001, pp. 442-444.
Takimoto, “New Antifolates: Pharmacology and Clinical Applications,”The Oncologist, 1996, vol. 1, pp. 68-81.
Grant Proposal, “Mobiletrex (M-Trex) for the Prevention and/or Treatment of Coronary Heart Disease”, American Heart Association, Jan. 23, 2003, 35 pages.
Grant Application, “Anti-inflammatory Antifolate Therapy for Heart Disease”, Department of Health and Human Services, Jan. 23, 2003, 27 pages.
Choi et al., “Methotrexate and Mortality in Patients with Rheumatoid Arthritis: A Prospective Study”,The Lancet, 2002, pp. 1173-1177, vol. 359, Abstract only.
Dessein et al., “Effects of Disease Modifying Agents and Dietary Intervention on Insulin Resistance and Dyslipidemia in Inflammatory Arthritis: A Pilot Study”,Arthritis Res. 2002, pp. 1-7, vol. 4, No. 6.
Park et al., “Effects of Antirheumatic Therapy on Serum Lipid Levels in Patients with Rheumatoid Arthritis: A Prospective Study”,Am. J. Med., 2002, pp. 188-193, vol. 113, No. 3, Abstract only.
McGuire, et al., “Metabolism-blocked Antifolates as Potential Anti-rheumatoid Arthritis Agents: 4-Amino-4-deoxy-5,8,10-trideazapteroyl—D,L-4′-methyleneglutamic Acid (CH-1504) and Its Analogs,”Biochemical Pharmacology, 2009, pp. 1161-1172, vol. 77, No. 7.
Nair et al., “Metabolism-Blocked Antifolates, 3: Enantiomers of 4′methylene-5,8,10-Trideazaaminopterin (M-Trex),”Proceedings of the American Association for Cancer Research Annual Meeting, 2001, pp. 294, vol. 42. (Abstract No. 1583).
Pedder Simon
Roberts Michael J.
Acevedo James H Alstrum
Chelsea Therapeutics, Inc.
Richter Johann R
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Metabolically inert antifolates for treating disorders of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolically inert antifolates for treating disorders of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolically inert antifolates for treating disorders of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245944